Table 4 Univariable and multivariable meta-regression models for HCV antibody prevalence among the general population in Egypt.
Number of studies | Univariable analyses | Multivariable analysis* | ||||
|---|---|---|---|---|---|---|
OR (95% CI) | p-value** | AOR (95% CI) | p-value‡ | |||
Subpopulation type (among the general population) | Blood donors | 111 | 1 | 1 | ||
Pregnant women/ANC attendees | 13 | 0.86 (0.46–1.63) | 0.651 | 1.11 (0.62–1.96) | 0.729 | |
Children | 16 | 0.40 (0.22–0.71) | 0.002** | 0.47 (0.27–0.79) | 0.005‡ | |
Egyptian expatriate workers undergoing mandatory pre-employment screening and Egyptians living abroad | 23 | 1.45 (0.88–2.37) | 0.141 | 0.98 (0.43–2.21) | 0.956 | |
Other general population groups | 99 | 1.47 (1.09–1.98) | 0.012** | 1.63 (1.17–2.28) | 0.004‡ | |
Region | Upper Egypt | 9 | 1 | 1 | ||
Middle Egypt | 54 | 1.69 (0.78–3.67) | 0.186 | 1.57 (0.79–3.12) | 0.199 | |
Lower Egypt | 89 | 2.42 (1.14–5.14) | 0.022** | 1.92 (0.98–3.75) | 0.057 | |
Canal & Sinai | 16 | 1.65 (0.67–4.06) | 0.271 | 0.62 (0.27–1.40) | 0.247 | |
National | 24 | 1.48 (0.64–3.45) | 0.357 | 0.86 (0.36–2.06) | 0.735 | |
Mixed regions | 39 | 4.00 (1.80–8.87) | 0.001** | 1.85 (0.80–4.27) | 0.150 | |
Regions outside Egypt | 15 | 2.58 (1.04–6.41) | 0.041** | 2.41 (0.75–7.71) | 0.139 | |
Unspecified | 16 | 3.24 (1.32–7.96) | 0.011** | 1.62 (0.73–3.63) | 0.236 | |
Study site | Blood bank | 77 | 1 | |||
National | 24 | 0.68 (0.40–1.14) | 0.143 | — | — | |
Clinical | 72 | 1.04 (0.72–1.49) | 0.844 | — | — | |
Others | 74 | 1.08 (0.75–1.56) | 0.663 | — | — | |
Unspecified | 15 | 1.56 (0.83–2.92) | 0.167 | — | — | |
Sampling methodology | Probability-based | 66 | 1 | |||
Non-probability based | 196 | 0.72 (0.53–0.99) | 0.044** | 0.70 (0.46–1.05) | 0.086 | |
Sample size | <100 | 63 | 1 | |||
>=100 | 199 | 0.73 (0.53–1.00) | 0.052** | 1.14 (0.85–1.54) | 0.385 | |
Publication year | 262 | 0.93 (0.92–0.95) | 0.000** | 0.94 (0.92–0.96) | 0.000‡ | |
Median year of data collection | 197 | 1.0 | 0.458 | — | — | |
